Established in November 2014, Amgen’s Next-Generation Biomanufacturing facility in Singapore heralds a new juncture of efficient and innovative commercial-scale production of medicines. VP of Singapore Site Operations, Arleen Paulino, pinpoints the elements that distinguish this facility from current standards in manufacturing, while highlighting the key role that this facility will play in Amgen’s global supply chain when becoming fully operational in 2017.
Could you introduce yourself to our international readers as well as the scope of your role and responsibilities as the vice president of site operations here in Singapore?
Our Next-Generation Biomanufacturing facility is our newest manufacturing site and the first in Asia, which uses a revolutionary approach incorporating multiple technologies to enable greater speed, productivity and flexibility
